title: A phase II trial of oral 4'demethoxydaunorubicin in advanced colorectal carcinoma.
abstract: 4'Demethoxydaunorubicin (DMDR), an orally active daunorubicin analogue, was administered to 22 patients with advanced colorectal carcinoma. Patients were stratified into good- and poor-risk categories and received doses of 45 mg/m2 and 40 mg/m2, respectively, at 28-day intervals. Twenty-one patients were evaluable for response. No tumour responses occurred, although six patients had stable disease. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 45% of patients. Marrow toxicity was common and usually mild. DMDR appears to have no useful activity in colorectal carcinoma.
authors.affiliation: Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Presgrave
authors.forename: R
authors.initials: R
authors.lastname: Woods
authors.forename: D
authors.initials: D
authors.lastname: Dalley
authors.forename: D
authors.initials: D
authors.lastname: Bell
authors.forename: J
authors.initials: J
authors.lastname: Levi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged
chemical_list: D015255:Idarubicin